drugset / Trial / NCT02242279
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
RandomizedCrossoverDouble-blindTreatment
Summary
Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)
Timeline
- Start
- 2004-06
- Primary completion
- 2004-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEA 2180 BR | Unknown | 80 ug | Inhaled |
| Subject | BEA 2180 BR | Unknown | 200 ug | Inhaled |
| Subject | BEA 2180 BR | Unknown | 800 ug | Inhaled |
| Comparator | Tiotropium | Other / unclassified | 72 ug | — |